Premium
HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non‐small cell lung cancer
Author(s) -
SHIM Byoung Yong,
KIM Chi Hong,
AHN Myeong Im,
KIM Sung Whan,
CHO Deog Gon,
CHO Kyo Do,
YOO Jinyoung,
KIM HoonKyo
Publication year - 2009
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2009.01244.x
Subject(s) - cish , chromogenic in situ hybridization , taxane , medicine , oncology , lung cancer , hazard ratio , gene duplication , cisplatin , chemotherapy , immunohistochemistry , cancer , gene expression , gene , breast cancer , biology , in situ hybridization , confidence interval , biochemistry
Aim: The aim of this study was to assess the role of various HER2 , tau and bcl2 as prognostic markers of responsiveness to taxane and cisplatin therapy in patients with advanced NSCLC. Methods: Amplification of HER2 gene determined by chromogenic in situ hybridization (CISH) and HER2 , tau and bcl2 protein expression determined by immunohistochemistry were assessed in 49 patients with NSCLC enrolled in our four clinical trials of taxane plus cisplatin chemotherapy. Results: The patients were classified as responders or non‐responders, a negative tau expression was associated with a significantly higher rate of response compared to a positive tau expression ( OR 3.33, 95% CI 1.01–10.97, P = 0.043). Patients with more than stable disease compared to those with progressive disease showed that negative amplification of the HER2 gene was associated with a significantly higher rate of disease control compared to positive amplification ( OR 7.35, 95% CI 0.83–65.21, P = 0.048). Furthermore, HER2 gene amplification was strongly associated with the overall survival: 20 months (95% CI 9.007–30.993) in patients with negative amplification of the HER2 gene versus 12 months (95% CI 6.584–17.416) in patients with positive amplification of the HER2 gene ( P = 0.040). A multivariate analysis with the Cox proportional hazards model confirmed that HER2 gene amplification was a significant independent prognostic factor with a hazard ratio of 2.334 (95% CI 1.060–5.142, P = 0.035). Conclusion: Tau protein expression and HER2 gene amplification are the prognostic factors in NSCLC patients treated with a taxane and cisplatin combination.